Topical nepafenac in the treatment of diabetic macular edema

Figures & data

Figure 1 A OCT image of left eye in Patient #3 at baseline. Central subfield thickness was 517 μm and total volume was 9.02 mm³. B OCT image of left eye in Patient #3 after 259 days of nepafenac treatment. Central subfield thickness was 158 μm and total volume was 7.35 mm³.

Table 1 Demographics, visual acuity, foveal thickness, and hemoglobin A1c (HbA1c) results before and after nepafenac treatment

Patient	Age sex	Eye	Baseline vision	Final vision	Days to final vision	Baseline foveal thickness (μm)	Final foveal thickness (μm)	Days to final foveal thickness	Initial Hba1c%	Final HbA1c%
1	65 M	OS	20/80	20/50	193	378	215	193	7.0	6.8
2	68 M	OS	20/40	20/40	209	286	226	209	6.5	6.8
3	66 F	OS	20/240	20/140	259	517	158	259	7.3	9.4
4	68 F	OS	20/120	20/80	227	599	423	227	4.9	6.0
5	76 M	OD	20/80	20/70	182	342	267	91
5		OS	20/400	20/400	182	380	310	91